WNT signaling modulates PD-L1 expression in the stem cell compartment of triple-negative breast cancer.
Aldehyde Dehydrogenase
/ metabolism
Animals
B7-H1 Antigen
/ metabolism
Biomarkers, Tumor
/ metabolism
Cell Line, Tumor
Down-Regulation
/ physiology
Female
Humans
Hyaluronan Receptors
/ metabolism
Mice, Inbred BALB C
Stem Cells
/ metabolism
Triple Negative Breast Neoplasms
/ metabolism
Up-Regulation
/ physiology
Wnt Signaling Pathway
/ physiology
Journal
Oncogene
ISSN: 1476-5594
Titre abrégé: Oncogene
Pays: England
ID NLM: 8711562
Informations de publication
Date de publication:
05 2019
05 2019
Historique:
received:
05
05
2018
accepted:
07
12
2018
revised:
03
12
2018
pubmed:
2
2
2019
medline:
12
10
2019
entrez:
2
2
2019
Statut:
ppublish
Résumé
Triple-negative breast cancers (TNBCs) are characterized by a poor prognosis and lack of targeted treatments, and thus, new therapeutic strategies are urgently needed. Inhibitors against programmed death-1 (PD-1)/PD-1 ligand (PD-L1) have shown significant efficacy in various solid cancers, but their activity against TNBCs remains limited. Here, we report that human TNBCs molecularly stratified for high levels of PD-L1 (PD-L1
Identifiants
pubmed: 30705400
doi: 10.1038/s41388-019-0700-2
pii: 10.1038/s41388-019-0700-2
pmc: PMC6755989
doi:
Substances chimiques
B7-H1 Antigen
0
Biomarkers, Tumor
0
CD274 protein, human
0
Hyaluronan Receptors
0
Aldehyde Dehydrogenase
EC 1.2.1.3
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
4047-4060Références
J Immunol Methods. 2009 Aug 15;347(1-2):70-8
pubmed: 19567251
Cell Rep. 2016 Sep 27;17(1):233-248
pubmed: 27681434
Int J Cancer. 2017 Oct 1;141(7):1402-1412
pubmed: 28614911
Nat Commun. 2018 May 15;9(1):1908
pubmed: 29765039
J Clin Pathol. 2017 Oct;70(10):860-867
pubmed: 28373294
Am J Pathol. 2010 Jun;176(6):2911-20
pubmed: 20395444
CA Cancer J Clin. 2016 Jan-Feb;66(1):7-30
pubmed: 26742998
Cell Rep. 2017 Jan 3;18(1):248-262
pubmed: 28052254
Nat Commun. 2016 Aug 30;7:12632
pubmed: 27572267
Oncologist. 2015 Oct;20(10):1189-98
pubmed: 26306903
Nat Rev Cancer. 2012 Mar 22;12(4):252-64
pubmed: 22437870
Oncogenesis. 2017 Apr 3;6(4):e310
pubmed: 28368389
J Clin Oncol. 2014 Sep 20;32(27):2959-66
pubmed: 25071121
N Engl J Med. 2006 Sep 21;355(12):1253-61
pubmed: 16990388
Front Oncol. 2014 Mar 18;4:53
pubmed: 24672774
Expert Opin Ther Targets. 2015 Feb;19(2):201-11
pubmed: 25491730
Bioinformatics. 2009 Jan 15;25(2):288-9
pubmed: 19033274
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Cancer. 2015 Jan 1;121(1):8-16
pubmed: 25043972
BMC Cancer. 2013 Nov 10;13:537
pubmed: 24209998
PLoS One. 2015 Feb 06;10(2):e0117097
pubmed: 25658419
J Clin Oncol. 2016 Jul 20;34(21):2460-7
pubmed: 27138582
Mol Cancer. 2015 Aug 07;14:149
pubmed: 26245467
J Clin Oncol. 2013 Mar 1;31(7):860-7
pubmed: 23341518
Nature. 2012 Oct 4;490(7418):61-70
pubmed: 23000897
Breast Cancer Res. 2010;12(5):R68
pubmed: 20813035
Nat Genet. 2000 May;25(1):25-9
pubmed: 10802651
Cancer Res. 2011 Mar 1;71(5):1772-80
pubmed: 21169407
Oncologist. 2017 Sep;22(9):1086-1093
pubmed: 28559413
Cancer Immunol Res. 2014 Apr;2(4):361-70
pubmed: 24764583
Crit Rev Oncol Hematol. 2017 Aug;116:116-124
pubmed: 28693793
Mod Pathol. 2011 Feb;24(2):209-31
pubmed: 21076461
Cancer Cell. 2016 Dec 12;30(6):925-939
pubmed: 27866850
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50
pubmed: 16199517
Pharmacol Ther. 2018 Jul;187:13-30
pubmed: 29421575
Nat Commun. 2013;4:2612
pubmed: 24113773
Sci Transl Med. 2016 Mar 2;8(328):328rv4
pubmed: 26936508
J Transl Med. 2017 Oct 11;15(1):205
pubmed: 29020960
Clin Cancer Res. 2016 Jul 15;22(14):3571-81
pubmed: 26864211
Genes Dis. 2016 Mar;3(1):11-40
pubmed: 27077077
Cancer Cell. 2018 Feb 12;33(2):187-201.e10
pubmed: 29438695
Breast Cancer Res. 2012 Mar 15;14(2):R48
pubmed: 22420471
Front Immunol. 2014 Jul 29;5:360
pubmed: 25120546
Sci Rep. 2015 Jul 23;5:12465
pubmed: 26202299
J Exp Med. 2017 Apr 3;214(4):895-904
pubmed: 28302645